BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
21 janv. 2020 07h00 HE
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China
13 janv. 2020 07h00 HE
|
BeiGene, LTD.
- SYLVANT® and QARZIBA®▼ recently listed for fast-track approval in China – - Expands EUSA’s global product offering; broadens BeiGene’s portfolio – HEMEL HEMPSTEAD, England and CAMBRIDGE, Mass. and...
BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference
08 janv. 2020 07h30 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
02 janv. 2020 08h15 HE
|
BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies
27 déc. 2019 22h30 HE
|
BeiGene, LTD.
Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophages BEIJING, China and...
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma
22 déc. 2019 18h00 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., Dec. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
16 déc. 2019 07h00 HE
|
BeiGene, LTD.
- Primary Endpoint of Statistical Superiority Related to Deep Response (VGPR or Better) Was Not Met; However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)-...
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
13 déc. 2019 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting
08 déc. 2019 16h45 HE
|
BeiGene, LTD.
Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma Poster presentation on data from clinical trial of BRUKINSA combined with...
BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference
26 nov. 2019 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...